Maris Research

Neptune lets Cygnus subsea inspection contract

Share on facebook
Share on facebook
Share on twitter
Share on linkedin

Neptune Energy today let a subsea inspection contract to Fugro for work on Cygnus gas field in the UK southern North Sea.

Fugro will employ survey technology to inspect the subsea infrastructure, including pipelines and structures, and to undertake survey activities in advance of future drilling campaigns on the field.

Data processing will be carried out from Fugro’s remote operations center in Aberdeen.

Cygnus field produces more than 250 MMcfd of natural gas. Two drilling centers target 10 wells. Cygnus Alpha consists of three bridge-linked platforms: a wellhead drilling center, a processing-utilities unit, and a living quarters-central control room. Cygnus Bravo, an unmanned satellite platform, lies 7 km northwest of Cygnus Alpha.

Gas is exported via a 55 km pipeline. Cygnus connects via the Esmond Transmission System (ETS) pipeline to the gas-treatment terminal at Bacton, Norfolk.

Neptune is operator of Cygnus field with 38.75% interest. Spirit Energy holds 61.25%. 

... continue reading 3rd party author's post at source website

order-1586392_1280

Can't Get Enough Freebies? Subscribe to our Newsletter!

We will send you free research and analysis summarized at the end of each month.

Leave a Comment

Newsletter Sign up

Top Posts

PLACE HOLDER FOR AD PAGE – SEE 18:– OF VIDEO.€

What is Flywheel?

notes-150587_1280

More Articles.

rjmaris

Etiam ultrices mollis faucibus

Maecenas pharetra risus sit amet gravida fermentum. Mauris vitae magna maximus, tempus neque ac, feugiat velit. Etiam a enim nec quam fringilla cursus. In porttitor elit mi, at tempor lorem fringilla vitae. Proin in egestas purus. Cras vestibulum efficitur tempor. Morbi magna nisl, sollicitudin nec quam in, tempor convallis dolor. Nullam eu urna magna. Suspendisse…

Read More »
rjmaris

China Regulator Accepts Akeso, Sino Biopharm Application For Cancer Drug

https://thumbor.forbes.com/thumbor/fit-in/0x0/filters:format(jpg)/https://specials-images.forbesimg.com/imageserve/610b8c15eac20144988a6113/0x0.jpgChina’s National Medical Products Administration has accepted a new drug application from mainland pharmaceutical suppliers Akeso and Sino Biopharmaceutical for treatment of nasopharygeal cancer, or NPC. Hong Kong-traded shares in both companies rose after the announcement this morning, though fell back later amid a broader selloff amid concerns on the spread of the Delta variant

Read More »

Get content like this sent directly to your inbox!

Follow OnceBurned

Share on facebook
Share on twitter
Share on linkedin
Scroll to Top